01:20:59 EST Fri 22 Jan 2021
Enter Symbol
or Name

Login ID:
Trillium Therapeutics Inc (2)
Symbol TRIL
Shares Issued 98,378,265
Close 2020-11-02 C$ 16.49
Recent Sedar Documents

Trillium forms scientific advisory board

2020-11-02 16:22 ET - News Release

Mr. James Parsons reports


Trillium Therapeutics Inc. has formed a scientific advisory board (SAB), including Karen Ferrante, MD, Gordon Freeman, PhD, Tom Reynolds, MD, PhD, Steven Rosen, MD, and Jeff Settleman, PhD.

"It is a true privilege to announce this SAB, comprised of leading experts who have had major formative impact on the field of oncology/immuno-oncology over the past 25 years," said Jan Skvarka, Trillium's president and chief executive officer. "Their combined resume includes several of the most groundbreaking oncology drugs or underlying scientific discoveries, including the PD-1/PD-L1 class, Adcetris, interferon, Iressa, Lemtrada, Velcade, Tarceva, Taxol and Xalkori, among others. We are looking forward to their guidance as we continue expanding our research and development activities."

Members of the Trillium SAB

Dr. Ferrante, MD

Dr. Ferrante is a hematologist-oncologist with 25 years of experience in oncology drug development. She was the head of research and development and chief medical officer at Tokai Pharmaceuticals, and head of the oncology therapeutic area at Takeda and CMO at Millennium Pharmaceuticals, after holding a variety of roles in oncology clinical development at Pfizer and BMS. During her career she was involved in the clinical development of a number of important cancer therapeutics including Taxol, Tarceva and Velcade.

Dr. Freeman, PhD

Dr. Freeman is an immunology researcher in the department of medical oncology at Dana-Farber Cancer Institute and a professor of medicine at Harvard Medical School. Dr. Freeman is best known for the discovery of the PD-1/PD-L1 pathway, which provided the foundation for developing immune checkpoint blockade immunotherapies. Dr. Freeman is the 2014 recipient of the William B. Coley Award for distinguished research in tumour immunology, the 2017 recipient of the Warren Alpert Foundation award and a 2020 co-recipient of the Richard V. Smalley MD award, the highest award of the Society for Immunotherapy of Cancer.

Dr. Reynolds, MD, PhD

Dr. Reynolds served as CMO of Seattle Genetics, where he was responsible for building and leading an integrated clinical development, regulatory and medical affairs organization, highlighted by the development and approval of Adcetris. Previously, Dr. Reynolds served at ZymoGenetics (acquired by Bristol-Myers Squibb in 2010), most recently as vice-president of medical affairs, where he oversaw the clinical development and regulatory filing of recothrom, and vice-president of clinical affairs at Targeted Genetics.

Dr. Rosen, MD

Dr. Rosen is the provost and chief scientific officer of the City of Hope National Medical Center in Duarte, Calif. In addition to directing City of Hope's Comprehensive Cancer Center, Dr. Rosen leads the Beckman Research Institute at City of Hope. Previously, Dr. Rosen was the director of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University. In 2015, Dr. Rosen received a lifetime achievement award from the Israel Cancer Research Fund for his work in cancer research. His main areas of research involve the development of new treatments, particularly for hematologic malignancies.

Dr. Settleman, PhD

Dr. Settleman is the CSO for oncology R&D at Pfizer, where he leads all oncology research from discovery to proof-of-concept clinical studies. Prior to Pfizer, Dr. Settleman was the head of oncology research at Calico Life Sciences and the head of discovery oncology at Genentech, following an 18-year career in academia as a professor at the Harvard School of Medicine, a director of the Center for Molecular Therapeutics and scientific director of the Massachusetts General Hospital Cancer Center, as well as the head of the cancer cell biology program of the Dana-Farber/Harvard Cancer Center.

About Trillium Therapeutics Inc.

Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company's two clinical programs, TTI-621 and TTI-622, target CD47, a "don't eat me" signal that cancer cells frequently use to evade the immune system.

We seek Safe Harbor.

© 2021 Canjex Publishing Ltd. All rights reserved.